Immunicum Appoints New Experts in Cancer Immunology to Scientific Advisory Board

Press Release

30 September 2021

Immunicum Appoints New Experts in Cancer Immunology to Scientific Advisory Board

Immunicum AB (publ; IMMU.ST) today announced the appointment of Ada M. Kruisbeek, PhD, Sjoerd H. van der Burg, PhD, and Tanja D. de Gruijl, PhD, to its Scientific Advisory Board (SAB). These leading experts in cancer immunology were previously members of the SAB of DCprime and will join existing Immunicum SAB members, Inge Marie Svane, MD, PhD, and Pawel Kalinski MD, PhD. Dr Kruisbeek will serve as chair of the SAB.

“The appointments of renowned leaders like Ada, Sjoerd and Tanja adds to the depth of expertise of our SAB in oncology and cancer immunotherapy and broadens our access to an international network of clinical and scientific advisors as well as academic collaborators,” said Alex Karlsson-Parra, MD, PhD, CSO of Immunicum.Their insights will be essential as we continue to develop our allogeneic dendritic cell candidates, ilixadencel and DCP-001, to address key challenges in cancer therapy.”

The new members of Immunicum’s SAB include:

Ada M. Kruisbeek, PhD – Dr Kruisbeek previously served as Chief Scientific Officer at DCprime, which she founded in 2005. She has worked at the National Cancer Institute in Bethesda, USA, and previously held the position of Head of the Department of Immunology at the NKI-AVL (Netherlands Cancer Institute and Antoni van Leeuwenhoekziekenhuis Hospital) in Amsterdam. She is an Emeritus Professor of Immunology at VU University, Amsterdam where she also served as scientific director of the Life Sciences Center and the Technology Transfer Office of the VU.

Sjoerd van der Burg, PhD - Dr Sjoerd van der Burg is a Professor in Experimental Cancer Immunology and Therapy at the Department of Medical Oncology of the Leiden University Medical Center and Senior Investigator at the Oncode Institute in The Netherlands. His group performs fundamental, translational, and clinical studies focusing on factors of host-tumor interactions that determine the success and failure of immune system control of cancer. Dr van der Burg has extensive experience in monitoring innate and adaptive immune responses and exploits this to guide the development of cancer therapies. He has a PhD in immunology from Leiden University.

Tanja de Gruijl, PhD - Dr Tanja de Gruijl is a Professor of Translational Tumor Immunology and holds a Fenna Diemer Lindeboom Chair at the Amsterdam University Medical Center where she also heads the immunotherapy and immune monitoring lab. Her research ranges from preclinical studies to monitoring of Phase I-III clinical trials and includes topics such as the immune potentiation of tumor-draining lymph nodes and the tumor microenvironment, immunological arming of oncolytic adenoviruses, and nanobody-mediated targeting of Natural Killer T-cell subsets. Dr de Gruijl supervised the research that supported the foundation of DCprime. She has recently been elected to the board of directors of the Society for the Immunotherapy of Cancer (SITC). Dr de Gruijl holds a PhD in tumor immunology from the VU Amsterdam.

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting
Chief Executive Officer
Telephone: +31 713 322 627
E-mail: ir@immunicum.com

INVESTOR RELATIONS

Kristina Windrup Olander
Spikinc AB
Telephone: +46 72 545 34 74
E-mail: ir@immunicum.com

MEDIA RELATIONS

Sophia Hergenhan & Jacob Verghese
Trophic Communications
Telephone: +49 89 2388 7731
E-mail: immu@trophic.eu


ABOUT IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm.
www.immunicum.com

Attachment